ASCO: Revolution poised to capture RAS space as pancreatic cancer dataset ‘derisks’ approval

Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.